The decision to conduct a remote pharmaceutical audit or an on-site audit depends on various factors and should be made based on a risk-based approach, regulatory requirements, and the specific circumstances of the audit. Here are some considerations for when it may be appropriate to conduct either type of audit:

Remote Pharmaceutical Audit:

  1. Low-Risk Areas: For low-risk processes, suppliers, or facilities, where the impact on product quality and patient safety is minimal, a remote audit may be suitable.
  2. Travel Limitations: During extraordinary circumstances (e.g., pandemics, travel restrictions), when it is not feasible or safe to travel, a remote audit can be a practical alternative.
  3. Routine Surveillance: For periodic surveillance audits, where there is a well-established relationship with the auditee, and previous on-site audits have demonstrated a strong compliance record, a remote audit may be considered.
  4. Document Review: When the focus of the audit is primarily on reviewing documentation, such as quality management system records, batch documentation, and standard operating procedures, a remote audit can be effective.
  5. Information Availability: If the auditee has comprehensive electronic documentation and systems in place, which can be securely accessed remotely, it may support a remote audit.

On-Site Pharmaceutical Audit:

  1. High-Risk Areas: For critical processes, high-risk suppliers, or complex facilities where product quality and patient safety are of utmost concern, an on-site audit is preferred to have a firsthand assessment.
  2. Initial Audits: For new suppliers, contract manufacturing organizations (CMOs), or facilities, an on-site audit is crucial to evaluate their capabilities, infrastructure, and compliance with regulations.
  3. Process Observation: When the audit requires physical observation of manufacturing processes, environmental conditions, or personnel practices, an on-site audit is necessary.
  4. Physical Samples: If the audit involves sample collection or examination of physical products, materials, or equipment, an on-site presence is required.
  5. Facility and Equipment Inspection: On-site audits are essential to inspect facilities, equipment, and utilities to ensure compliance with GMP requirements.
  6. Cultural Assessment: For audits that involve evaluating the organization’s culture, employee behavior, and overall compliance culture, an on-site audit provides a more comprehensive perspective.
  7. Sensitive Information: In cases where sensitive or proprietary information needs to be discussed, an on-site audit may be preferred to ensure confidentiality.

Hybrid Approach: In some situations, a combination of remote and on-site audits (hybrid approach) may be appropriate. For instance, a remote audit could be conducted initially to assess documentation, followed by an on-site visit to validate processes and observations.

Ultimately, the decision to choose between a remote or on-site pharmaceutical audit should be based on careful consideration of the risks involved, the audit objectives, the resources available, and compliance with regulatory requirements. Regardless of the type of audit, the auditors must ensure that the audit process remains rigorous, objective, and compliant with applicable regulations and guidelines.

For more information on our QP Audits

For any questions get in touch with us at info@miaspharma.com